Literature DB >> 15538929

The glucagonoma syndrome and necrolytic migratory erythema: a clinical review.

Andre P van Beek1, Ellen R M de Haas, Willem A van Vloten, Cees J M Lips, Janine F M Roijers, Marijke R Canninga-van Dijk.   

Abstract

The glucagonoma syndrome is a rare disease in which a typical skin disorder, necrolytic migratory erythema, is often one of the first presenting symptoms. Weight loss and diabetes mellitus are two other prevalent characteristics of this syndrome. Necrolytic migratory erythema belongs to the recently recognized family of deficiency dermatoses of which zinc deficiency, necrolytic acral erythema and pellagra are also members. It is typically characterized on skin biopsies by necrolysis of the upper epidermis with vacuolated keratinocytes. In persistent hyperglucagonemia, excessive stimulation of basic metabolic pathways results in diabetes mellitus at the expense of tissue glycogen stores, and muscle and fat mass. Multiple (essential) nutrient and vitamin B deficiencies develop, which contribute to the dermatosis. In addition, glucagonomas may produce various other products, like pancreatic polypeptide, that add to the catabolic effects of glucagon.

Entities:  

Mesh:

Year:  2004        PMID: 15538929     DOI: 10.1530/eje.0.1510531

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  31 in total

1.  Abdominal mass, anemia, diabetes mellitus, and necrolytic migratory erythema.

Authors:  Motaz Qadan; Brendan Visser; Jinah Kim; Reetesh Pai; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-11-17       Impact factor: 3.199

2.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

3.  Glucagonoma syndrome with atypical necrolytic migratory erythema.

Authors:  Shujuan He; Weihui Zeng; Songmei Geng; Jinjing Jia
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

4.  Necrolytic migratory erythema.

Authors:  Hyun Ji Lee; Yong Hyun Jang
Journal:  CMAJ       Date:  2019-03-11       Impact factor: 8.262

5.  Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.

Authors:  Shiro Kimbara; Yutaka Fujiwara; Masanori Toyoda; Naoko Chayahara; Yoshinori Imamura; Naomi Kiyota; Toru Mukohara; Atsushi Fukunaga; Masahiro Oka; Chikako Nishigori; Hironobu Minami
Journal:  Clin J Gastroenterol       Date:  2014-04-09

Review 6.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

Review 7.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

Review 8.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

9.  Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.

Authors:  Stephanie A C Halvorson; Erin Gilbert; R Samuel Hopkins; Helen Liu; Charles Lopez; Michael Chu; Marie Martin; Brett Sheppard
Journal:  J Gen Intern Med       Date:  2013-05-17       Impact factor: 5.128

Review 10.  Do glucagonomas always produce glucagon?

Authors:  Nicolai Jacob Wewer Albrechtsen; Benjamin G Challis; Ivan Damjanov; Jens Juul Holst
Journal:  Bosn J Basic Med Sci       Date:  2016-02-01       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.